Enroll in Research > Research Search & Enroll Tool > Study Using M6620 (VX-970) An ATR Inhibitor to Treat Solid Tumors
Study Using M6620 (VX-970) An ATR Inhibitor to Treat Solid Tumors

Study Using M6620 (VX-970) An ATR Inhibitor to Treat Solid Tumors

Clinicaltrials.gov identifier:

Breast, Ovarian, Pancreatic, Prostate, Melanoma, Colorectal, Endometrial

Study Contact Information:

Gregory M Cote, MD, PhD by phone: 617-724-4000 or by email

A Non-Randomized Phase II Research Study of M6620 (VX-970) in Selected Solid Tumors to Inhibit the ATR Enzyme.

About the Study

This clinical trial is studying how well M6620 works in treating patients with advanced solid tumors. M6620 is a drug designed to block the ATR enzyme. ATR repairs damaged DNA. In cancer, ATR may protect the cancer cells by helping them repair damage. Blocking ATR may keep cancers from repairing their damaged DNA; slowing the growth of, or killing cancer cells. The study is open to people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation. The study will be recruiting people with different types of cancer, including people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation. 

Type of Study

  • This is a non-randomized, open-label study.  All patients who enroll in the trial will receive the study medication.

What the Study Entails

  • Participants will receive M6620 intravenously (IV) over 60 minutes on Days 1, 4, 8, 11, 15, 18, 22, and 25 on a 28-day cycle
  • This cycles repeats every 28 days in the absence of disease progression
  • After 16 weeks (4 cycles), patients may receive M6620 weekly on days 1, 8, 15, and 22
  • Undergo on-treatment biopsy at Day 15

Study Locations

The following are participating institutions:

  • Massachusetts
    • Boston: Dana-Farber Cancer Institute
      • Contact Geoffrey I. Shapiro, MD by email 
    • Boston: Beth Israel Deaconess Medical Center 
      • Contact Glen Weiss, MD by email
    • Boston: Massachusetts General Hospital Cancer Center:
      • Contact Gregory M. Cote, MD, PhD, by phone: 617-724-4000 or by email
    • Boston: Boston Children Hospital:
      • Contact Katherine Janeway, MD by email 
This Study is Open To:

Men and women 18 years or old with an advanced solid tumor can participate if:

  • they have an inherited BRCA1BRCA2 or ATM mutation, or
  • they have an acquired (somatic) mutation in BRCA1 or BRCA2, ATM or another mutation within a known DNA-damage-repairing gene including BARD1, BRIP1, CDK12, CHEK2, FANCA, FANCC, FANCE, FANCF, FANCM, MRE11A, NBN, PALB2, RAD51B, RAD51C, or RAD51D based on tumor testing. 
  • they have a tumor that can be biopsied and they are willing to undergo tumor biopsy
  • they have tumor tissue available for analysis
This Study is Not Open To:

People are excluded if they:

  • have had chemotherapy, immune therapy, other investigational therapy, major surgery, or radiotherapy within 3 weeks prior to entering the study
  • have received oral tyrosine kinase inhibitors (TKIs) within 5 half-lives of study entry
  • have previously received treatment with an ATR inhibitor, including but not limited to M6620 (VX-970)
  • have untreated brain metastases 
  • are pregnant women
  • are HIV-positive
  • have a history of treatment for another malignancy within the last 3 years